T P Hanna
Overview
Explore the profile of T P Hanna including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wright F, Kellett S, Hong N, Sun A, Hanna T, Nessim C, et al.
Curr Oncol
. 2020 Jul;
27(3):e318-e325.
PMID: 32669939
Objective: The purpose of this guideline is to provide guidance on appropriate management of satellite and in-transit metastasis (itm) from melanoma. Methods: The guideline was developed by the Program in...
2.
Malone E, Saleh R, Yu C, Ahmed L, Pugh T, Torchia J, et al.
Curr Oncol
. 2019 Nov;
26(5):e618-e623.
PMID: 31708655
Cancer is a genetic disease resulting from germline or somatic genetic aberrations. Rapid progress in the field of genomics in recent years is allowing for increased characterization and understanding of...
3.
Murray C, Sivajohanathan D, Hanna T, Bradshaw S, Solish N, Moran B, et al.
Curr Oncol
. 2019 Mar;
26(1):e94-e99.
PMID: 30853814
Objective: The purpose of the present work was to develop evidence-based indications for Mohs micrographic surgery in patients with a diagnosis of skin cancer. Methods: The guideline was developed by...
4.
Hanna T, Nguyen P, Baetz T, Booth C, Eisenhauer E
Clin Oncol (R Coll Radiol)
. 2018 Sep;
30(10):609-617.
PMID: 30196844
Aims: New targeted drugs and immune therapies reported since 2010 for metastatic or unresectable melanoma (MM) have shown improved survival in randomised trials. We studied the uptake of these new...
5.
Hanna T, Baetz T, Xu J, Miao Q, Earle C, Peng Y, et al.
Curr Oncol
. 2017 Dec;
24(6):e503-e512.
PMID: 29270059
Background: Although high-dose interferon (hd-ifn) is the sole approved adjuvant systemic treatment for melanoma in many jurisdictions, it is toxic. We sought to assess the population-level effects of hd-ifn toxicity,...
6.
Hanna T, Shafiq J, Delaney G, Vinod S, Thompson S, Barton M
Radiother Oncol
. 2017 Dec;
126(2):191-197.
PMID: 29229506
Background: To describe the population benefit of radiotherapy in a high-income setting if evidence-based guidelines were routinely followed. Methods: Australian decision tree models were utilized. Radiotherapy alone (RT) benefit was...
7.
Jin C, Hanna T, Cook E, Miao Q, Brundage M
Clin Oncol (R Coll Radiol)
. 2017 Nov;
30(1):47-56.
PMID: 29103854
Aims: Guidelines recommend the discussion of adjuvant radiotherapy post-prostatectomy for prostate cancer patients with high-risk pathology to consider all of their treatment options. We determine whether patterns of radiotherapy referral...
8.
Yap M, Hanna T, Shafiq J, Ferlay J, Bray F, Delaney G, et al.
Clin Oncol (R Coll Radiol)
. 2016 Dec;
29(2):72-83.
PMID: 27916340
More than half of all cancer diagnoses worldwide occur in low- and middle-income countries (LMICs) and the incidence is projected to rise substantially within the next 20 years. Radiotherapy is...
9.
Booth C, Nanji S, Wei X, Peng Y, Biagi J, Hanna T, et al.
Clin Oncol (R Coll Radiol)
. 2016 Sep;
29(1):e29-e38.
PMID: 27663601
Aims: Although guidelines do not recommend adjuvant chemotherapy (ACT) for stage II colon cancer, many state that ACT may be considered in high-risk disease. Here we describe practice patterns and...
10.
Jin C, Brundage M, Cook E, Miao Q, Hanna T
Clin Oncol (R Coll Radiol)
. 2016 Jul;
28(12):783-789.
PMID: 27461732
Aims: Adjuvant radiotherapy post-prostatectomy has been shown to benefit patients with adverse pathology. It remains unclear whether salvage radiotherapy confers equivalent outcomes. Practice guidelines recommend referral to radiation oncology within...